First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyOpen Access

Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE

Research article (journal) | Peer reviewed

Details about the publication

JournalCancers
Volume12
Issue6
StatusPublished
Release year2020
Language in which the publication is writtenEnglish

Authors from the University of Münster

Albring, Jörn Christian
Angenendt, Linus
Berdel, Wolfgang Eduard
Berdel, Andrew
Berning, Björna
Bormann, Eike
Gerß, Joachim
Gerwing, Mirjam
Hansmeier, Anna Antonia
Harrach, Saliha
Hartmann, Wolfgang
Heindel, Walter Leonhard
Heinzow, Hauke
Keßler, Torsten
Krähling, Tobias
Lenz, Georg
Mesters, Rolf Michael
Schliemann, Christoph
Schwöppe, Christian
Stalmann, Ursula
Wardelmann, Eva Erika
Wildgruber, Moritz
Wilms, Christian